Our Story

LinusBio is a patient-centric, precision exposome medicine company headquartered in North Brunswick, NJ

Originating from the world’s leading exposome laboratory at Mount Sinai Health System, LinusBio has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin.

The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease, oncology and more.

PROGRAMS & EXPERTISE
PLATFORM
Dr. Manish Arora at the LinusBio lab

Roadmap

2013

2013

The world’s first Institute for Exposomic Research established at Mount Sinai in 2013 with Manish Arora, PhD as the co-founder and director of environmental exposure and precision environmental medicine laboratories, leading a team of over 50 scientists advancing research in a vast array of diseases that are national health priorities, including autism, ALS, cancers, and gastrointestinal disorders.
2013

2016

2016

Dr. Manish Arora awarded the U.S. Presidential Early Career Award for Scientists and Engineers (PECASE)
2016

2019

2019

NIH grants of $25 million awarded to Dr. Arora and researchers at the Mt. Sinai Institute for Exposomic Research
2019

2020

2020

  • LinusBio incorporated
  • Initial patents filed
2020

2021

2021

  • Spinoff from Mt. Sinai completed, and worldwide license and collaboration agreement announced
  • Strategic partnerships with two global biopharma companies initiated
  • FDA Breakthrough
    Device designation awarded to StrandDxTM – ASD to assess the likelihood of autism in children < 18 months old and to aid in diagnosis
    of autism
2021

2022

2022

  • Medical Device Regulatory Pathway for StrandDx™- ASD continued with FDA feedback and meetings
  • Closed Series A financing round with Bow Capital and GPV as co-leads
2022

2023

2023

  • Closed Series A2 funding round with increased valuation
  • Announced partnership with Y.A.C. Holdings, Japan, to scale lab output
2023

Future

Future

  • Establish licensed proprietary laboratory to make StrandDx™-  ASD available as a laboratory developed test for pilot programs
  • Determine novel molecular endpoints for collaboration partners’ drug discovery and clinical trials
Future

© 2023 Linus Biotechnology, Inc.

Sign up for company updates

Consent(Required)
Main Menu
Twitter Linkedin
Join Us
Join Us